Extending neoadjuvant chemotherapy in rectal cancer
Mené sur 259 patients atteints d'un cancer rectal de stade II-III, cet essai multicentrique de phase II évalue, du point de vue du taux de réponse complète pathologique et des événements indésirables, l'intérêt d'ajouter une chimiothérapie de type mFOLFOX6 entre une chimioradiothérapie néoadjuvante et une exérèse totale du mésorectum
Preoperative chemoradiation or short-course radiotherapy improves outcomes in rectal cancer. It diminishes local relapses and increases progression-free survival and, therefore, is regarded as standard of care. However, its effect on reducing metastatic disease or increasing survival has not been proven. Postoperative chemotherapy is of limited value in patients who initially received neoadjuvant chemoradiation or short-course radiation.4 Many physicians believe that better systemic treatment is needed to improve survival in these patients.
The Lancet Oncology , commentaire, 2014